ProfoundBio is a clinical-stage biotechnology company focused on the development of novel antibody-based therapeutics for patients with cancer. Built on internally developed, innovative, and proprietary technology platforms, ProfoundBio has developed a pipeline consisting of multiple ADC drug candidates targeting solid tumors and hematological malignancies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/13/24 | $112,000,000 | Series B |
Ally Bridge Group Janus Henderson Investors LifeSci Venture Partners Lilly Asia Ventures Logos Capital LYFE Capital Medicxi Nextech Invest Octagon Capital OrbiMed Advisors Piper Heartland Healthcare Capital RA Capital Management Surveyor Capital T. Rowe Price Associates | undisclosed |
